Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...